Market Overview

UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance

Related ENDP
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape
Endo's Paladin Labs Reports Canadian Introduction Of Veregen

In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00.

In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite <4 months as CEO, Mr. DeSilva showed an impressive grasp of the business and inspired confidence in his new model: 1) M&A will be a clear focus, 2) the decentralized ‘lean pharma' model is gaining credibility, & 3) a worst-case scenario now yields $3.58 EPS as a trough in 2014 before growth after '15. Raise target to $45.”

Endo Health Solutions closed on Thursday at $35.96.

Posted-In: Corey Davis JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ENDP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free